Pharming Group Q3 Earnings Forecast Lifted by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Analysts at HC Wainwright raised their Q3 2026 earnings estimates for Pharming Group in a research report issued on Thursday, October 22nd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.45 for the quarter, up from their previous estimate of $0.23. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Pharming Group’s Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.45 EPS.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

A number of other equities research analysts have also issued reports on PHAR. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Pharming Group to a “hold” rating in a research report on Saturday. Canaccord Genuity Group set a $38.00 price objective on Pharming Group in a research note on Wednesday, September 23rd. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $38.67.

Pharming Group Trading Up 6.3%

PHAR opened at $11.90 on Monday. The firm has a market capitalization of $842.28 million, a price-to-earnings ratio of 99.17 and a beta of -0.05. The company’s 50 day simple moving average is $10.69 and its two-hundred day simple moving average is $13.92. Pharming Group has a 1-year low of $9.11 and a 1-year high of $21.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd largest holding. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.